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ABSTRACT
The multidrug transporters breast cancer resistance protein
(BCRP), multidrug-resistance protein 1 (MDR1), and multidrug-
resistance–associated protein (MRP) 2 and 3 eliminate toxic
compounds from tissues and the body and affect the
pharmacokinetics of many drugs and other potentially toxic
compounds. The food-derived carcinogen PhIP (2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine) is transported by
BCRP, MDR1, and MRP2. To investigate the overlapping
functions of Bcrp1, Mdr1a/b, and Mrp2 in vivo, we generated
Bcrp1;Mdr1a/b;Mrp22/2 mice, which are viable and fertile.
These mice, together with Bcrp1;Mrp2;Mrp32/2 mice, were
used to study the effects of the multidrug transporters on the
pharmacokinetics of PhIP and its metabolites. Thirty minutes
after oral or intravenous administration of PhIP (1 mg/kg), the
PhIP levels in the small intestine were reduced 4- to 6-fold
in Bcrp1;Mdr1a/b;Mrp22/ 2 and Bcrp1;Mrp2;Mrp32/2 mice
compared with wild-type mice. Fecal excretion of PhIP was
reduced 8- to 20-fold in knockouts. Biliary PhIP excretion was
reduced 41-fold in Bcrp1;Mdr1a/b;Mrp22/2 mice. Biliary and
small intestine levels of PhIP metabolites were reduced in
Bcrp1;Mrp2-deficient mice. Furthermore, in both knockout
strains, kidney levels and urinary excretion of genotoxic PhIP-
metabolites were significantly increased, suggesting that
reduced biliary excretion of PhIP and PhIP metabolites leads
to increased urinary excretion of these metabolites and
increased systemic exposure. Bcrp1 and Mdr1a limited PhIP
brain accumulation. In Bcrp1;Mrp2;Mrp32/2, but not Bcrp1;
Mdr1a/b;Mrp2/2 mice, the carcinogenic metabolites N2-OH-
PhIP (2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyri-
dine) and PhIP-5-sulfate (a genotoxicity marker) accumulated
in liver tissue, indicating that Mrp3 is involved in the sinusoidal
secretion of these compounds. We conclude that Bcrp1,
Mdr1a/b, Mrp2, and Mrp3 significantly affect tissue disposition
and biliary and fecal elimination of PhIP and its carcinogenic
metabolites and may affect PhIP-induced carcinogenesis as
a result.
Introduction
The ATP-binding cassette (ABC) transporters P-glycoprotein
(P-gp or multidrug-resistance protein [MDR] 1 or ABCB1),
breast cancer resistance protein (BCRP or ABCG2), multidrug-
resistance protein (MRP) 2 (ABCC2), andMRP3 (ABCC3) have
very broad and substantially overlapping substrate specificities
and can actively extrude potentially toxic compounds from
cells. They are expressed in organs with excretory functions,
such as liver, kidney, and small intestine, and are involved
in the elimination of endogenous and exogenous compounds
from the body. P-gp, BCRP, and, to a lesser extent, MRP2 are
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additionally present in tissue sanctuaries, such as brain,
testis, and placenta, where they protect these important
organs from entry of potentially toxic compounds. Whereas
P-gp, BCRP, and MRP2 are located at the apical membrane of
epithelial cells, transporting their substrates into bile, feces,
and urine, MRP3 is located basolaterally in the intestine and
liver, where it transports its substrates into the blood
circulation (Borst and Elferink, 2002; Schinkel and Jonker,
2003; Leslie et al., 2005).
Besides endogenous compounds and a wide range of drugs,
the dietary heterocyclic amine carcinogens PhIP (2-amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine) and IQ (2-amino-3-
methylimidazo[4,5-f]quinoline) are also substrates for ABC
transporters in vitro and in vivo (Dietrich et al., 2001a,b; van
Herwaarden et al., 2003, 2006; Leslie et al., 2005; Vlaming
et al., 2006; Enokizono et al., 2008). PhIP is the most
abundant heterocyclic amine in fried or cooked meat, chicken,
and fish. In mice, PhIP primarily causes lymphomas and
tumors of the small intestine, whereas in rats it causes colon,
prostate, and mammary gland tumors. PhIP is rapidly taken
up after ingestion and heavily metabolized, leading to
detoxification products but also to activated, potentially
carcinogenic metabolites (Supplemental Fig. 1; Gooderham
et al., 2001, 2002; Lauber et al., 2004; Nakagama et al., 2005).
Here, we focused on the precarcinogen N2-OH-PhIP (2-hydroxy-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine), and the
derivatives of 5-OH-PhIP (2-amino-1-methyl-6-phenylimi-
dazo[4,5-b]-5-hydroxypyridine) and PhIP-5-sulfate, which
represent breakdown products of the ultimate genotoxic
nitrenium radical cation that also forms mutagenic PhIP-
DNA adducts. Therefore, 5-OH-PhIP and PhIP-5-sulfate are
considered good markers for genotoxic exposure upon PhIP
exposure. PhIP-N-sulfate and N-acetyl-PhIP, the primary
precursors of the genotoxic nitrenium radical, are too short-
lived to be detectable in pharmacokinetic studies. Further-
more, part of the carcinogenic potential of PhIP may also be
explained by the fact that PhIP possesses estrogenic activity
and could therefore stimulate cell proliferation (Schut and
Snyderwine, 1999; Frandsen and Alexander, 2000; Gooderham
et al., 2002; Lauber et al., 2004; Chen et al., 2007; Lauber and
Gooderham, 2007, 2011).
Using Bcrp1- or Mrp2-deficient mice and rats, it was
previously shown that Bcrp1 andMrp2 significantly influence
the pharmacokinetics of [14C]PhIP in vivo (Dietrich et al.,
2001b; van Herwaarden et al., 2003, 2006; Vlaming et al.,
2006). However, since in several studies only radioactivity
wasmeasured, no differentiation between parent PhIP and its
mutagenic metabolites could be made. In Mrp2-deficient TR2
rats, it was found that Mrp2 influences the biliary excretion of
PhIP, 49-OH-PhIP and some glucuronide conjugates (Dietrich
et al., 2001a). Furthermore, in Bcrp12/2 mice, it was shown
that Bcrp1 restricts the penetration of PhIP, N2-OH-PhIP,
and 49-OH-PhIP into the brain or testis (Enokizono et al.,
2008). Murine Mdr1a transports [14C]PhIP in vitro, but no
effect of murine Mdr1a/b on [14C]PhIP plasma elimination
was found (van Herwaarden et al., 2003), perhaps as a result
of overlapping activity of Bcrp1 or Mrp2. The effect of other
ABC transporters on the pharmacokinetics of PhIP and its
metabolites has not been investigated yet.
To investigate the overlapping or complementary roles of
Bcrp1,Mdr1a/b, Mrp2, andMrp3 in vivo, we generated a set of
compound knockout mice, deficient in up to three of these
ABC transporters (Schinkel et al., 1997; Jonker et al., 2002;
Vlaming et al., 2006, 2008, 2009a,b). These strains proved to
be useful tools for pharmacokinetic studies. To be able to
determine the combined effects of the apically located trans-
porters Bcrp1, Mdr1a/b, and Mrp2 on physiology and
pharmacology, we have now generated Bcrp1;Mdr1a/b;
Mrp22/2 mice. Furthermore, we recently developed and
validated a liquid chromatography–tandem mass spectrome-
try (LC-MS/MS) assay for the quantitative determination of
PhIP and its metabolite N2-OH-PhIP in various matrices
from mice and expanded it to include multiple phase 1 and
phase 2 metabolites (Teunissen et al., 2010, 2011). We here
used the Bcrp1;Mdr1a/b;Mrp22/2 mice to investigate the
combined effect of Bcrp1, Mdr1a/b, and Mrp2 on the
elimination of PhIP and its metabolites in vivo. Furthermore,
as the basolateral transporter Mrp3 is often upregulated
when Mrp2 is absent, and thus may compensate for the
decreased apical (biliary) efflux from the liver (Donner and
Keppler, 2001; Zelcer et al., 2005; Vlaming et al., 2006), we
additionally investigated the pharmacokinetics of PhIP and
its metabolites in Bcrp1;Mrp2;Mrp32/2 mice (Vlaming et al.,
2009b).
Materials and Methods
Animals. In compliance with Dutch legislation, mice were housed
and handled according to institutional guidelines, and approval of the
local animal care and use committee was obtained before the start of
experiments.Bcrp1;Mdr1a/b;Mrp22/2mice were generated by cross-
breeding Bcrp1;Mdr1a/b2/2 (Jonker et al., 2002) and Bcrp1;Mrp22/2
(Vlaming et al., 2009a) mice. The generation of Bcrp1;Mrp2;Mrp32/2
mice was described before (Vlaming et al., 2009b). All animals were
of .99% Friend Virus B-type (FVB) background and 9–14 weeks old.
Animals were kept in a temperature-controlled environment with a
12-hour light/dark cycle. They received a standard diet (AM-II; Hope
Farms, Woerden, The Netherlands) and acidified water ad libitum.
Chemicals. PhIP and its deuterated internal standard D3-PhIP
[2-amino-1-(trideuteromethyl)-6-phenylimidazo[4,5-b]pyridine] were
purchased from Toronto Research Chemicals (North York, ON,
Canada). N2-OH-PhIP was purchased from the National Cancer
Institute Chemical Carcinogen Reference Standard Repository at the
Midwest Research Institute (Kansas City, MO). 5-OH-PhIP was
a kind gift from Henrik Frandsen of the National Food Institute,
Technical University of Denmark. Bovine serum albumin, dimethyl
sulfoxide (DMSO), and formic acid were purchased from Merck
(Darmstadt, Germany) and were used as received. Methanol was
obtained from Biosolve Ltd. (Amsterdam, The Netherlands). Distilled
water was from B. Braun (Melsungen, Germany). Ketamine was from
Parke-Davis (Hoofddorp, The Netherlands), xylazine from Sigma-
Aldrich (St. Louis, MO), andmethoxyflurane (Metofane) fromMedical
Developments Australia Pty. Ltd. (Springvale, VIC, Australia). All
other chemicals and reagents were from Sigma-Aldrich (Steinheim,
Germany).
Histologic, Clinical-Chemical, and Hematologic Analysis of
Bcrp1;Mdr1a/b;Mrp22/2 Mice. Histologic analysis of male and
female mouse tissues (n5 6), clinical chemistry analyses (including total
and conjugated bilirubin, alkaline phosphatase, aspartate aminotrans-
ferase, and alanine aminotransferase) on the serum of male and female
mice (n5 6), as well as standard hematologic analysis ofmale and female
mice (n 5 6, twice within a time span of 1.5 years), were performed as
described (Vlaming et al., 2006).
Real-Time Polymerase Chain Reaction Analysis. RNA iso-
lation, cDNA synthesis, and real-time quantitative polymerase chain
reaction analysis on liver, kidney, and small intestine of malemice (n5
3) were done as described (van Waterschoot et al., 2008).
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Pharmacokinetic Experiments. For oral administration, 10ml/g
of body weight of a 0.1 mg/ml PhIP solution in 20% (v/v) DMSO, and
5% (w/v) D-glucose was dosed by gavage in the stomach of male mice.
For intravenous administration, 5 ml/g of body weight of a 0.2 mg/ml
PhIP solution in 20% (v/v) DMSO and 0.9% (w/v) NaCl solution
was injected into the tail vein of male mice. Animals were killed by
terminal bleeding through cardiac puncture under methoxyflurane
anesthesia, and organs were removed. Intestinal contents and tissue
were separated.
Biliary Excretion of PhIP and Its Metabolites. Gallbladder
cannulations in male mice were performed as described (van
Herwaarden et al., 2003). After cannulation, PhIP was administered
intravenously at 1 mg/kg as described above. Bile was collected in
15-minute fractions for 60 minutes after administration of PhIP.
Subsequently, mice were killed by cardiac puncture and plasma and
organs were collected.
Fecal and Urinary Excretion of PhIP and Its Metabolites.
Male mice were individually housed in Tecniplast metabolic cages
(Milan, Italy) and allowed 24 hours to adapt before PhIP (1 mg/kg)
was injected into the tail vein, as described already herein. Feces and
urine were collected over 24 hours. Subsequently, mice were killed by
terminal bleeding through cardiac puncture under methoxyflurane
anesthesia. Organs were removed, and intestinal contents (feces) and
tissue were separated.
Sample Preparation. After sampling, urine, bile, and plasma
samples were snap-frozen. Tissue and feces samples were weighed
before snap-freezing. The complete organ or the total volume of
sampled feces was homogenized in a 4% (w/v) bovine serum albumin
solution using a Polytron blender. Feces homogenates were centri-
fuged for 10 minutes at 11,300g. A 10-ml volume of bile was diluted in
400 ml of 4% (w/v) bovine serume albumin solution.
Sample Processing. A 100-ml aliquot of plasma, diluted bile,
tissue, or clear supernatant of centrifuged feces homogenate was
processed immediately after thawing at ambient temperature by the
addition of 300 ml of internal standard (D3-PhIP) solution in
acetonitrile. The mixture was vortex-mixed for 10 seconds, followed
by centrifugation for 10 minutes at 11,300g; 100 ml of the clear
supernatant was diluted in a 1:1 ratio with 100 ml of 3.5 mM
ammonium formate buffer, pH 3.5. Urine was 10 diluted by
addition of a 180 ml of internal standard solution in methanol-
ammonium formate buffer, pH 3.5 (30:70, v/v) to a 20-ml urine
sample aliquot.
LC-MS/MS Analysis of PhIP and Its Metabolites. LC-MS/MS
was used for the separation and detection of PhIP and its metabolites.
Mobile phase A was prepared by adjusting a 5 mM ammonium
formate solution to pH 3.5 with a 98% formic acid solution. Mobile
phase B consisted of methanol. Mobile phase A and B were pumped
through a Synergi Hydro 110 Å column (150  2.0 mm I.D., 4 mm;
Phenomenex, Torrance, CA) at a flow rate of 0.2 ml/min.
The LC eluate was directed to an API 3000 triple quadrupole MS
(AB Sciex, Foster City, CA) equipped with an electrospray ion source
operating in the positive ion mode. For quantification, multiple-
reaction monitoring chromatograms were acquired and processed.
Calibration curves of analyte/internal standard peak area ratio
versus, respectively, PhIP and N2-OH-PhIP concentrations were
constructed, and a weighted 1/x2 (the reciprocal of the squared
concentration) linear regression was applied to the data. Quantifica-
tion of metabolites was performed based on the calibration curve
of PhIP. PhIP-glucuronides and OH-PhIP-glucuronide metabolites
(Supplemental Fig. 1) could not be unequivocally distinguished, as
reference standards were not available in all cases. Therefore, in this
study, PhIP-glucuronides stands for the sum of PhIP-N2-glucuronide
and PhIP-N3-glucuronide, and OH-PhIP-glucuronides is defined as
the sum of all OH-PhIP-glucuronides detected (Supplemental Fig. 1).
After purification from mouse urine, the identity of both PhIP-49-
sulfate and PhIP-5-sulfate was confirmed by NMR analysis (Teunissen
et al., 2011). The lower limit of quantification (LLQ) of PhIP and its
metabolites was 1 ng/ml.
Statistical Analysis. Unless otherwise indicated, the two-sided
unpaired Student’s t test was used to assess statistical significance
of differences between two sets of data. For analysis of statistical
difference when compared with data below the detection limit, cal-
culations were made based on the LLQ 6 LLQ. Results are presented
as the means6 S.D. Differences were considered statistically significant
when P , 0.05.
Results
Macroscopic and Microscopic Analysis of Bcrp1;
Mdr1a/b;Mrp22/2 Mice. Bcrp1;Mdr1a/b;Mrp22/2 mice were,
like Bcrp1;Mrp2;Mrp32/2 mice (Vlaming et al., 2009b), viable
and fertile, and they had normal life spans, body weights, and
anatomy. Adult male Bcrp1;Mdr1a/b;Mrp22/2 mice had a 46%
increased liver weight compared with wild-type mice (7.0% 6
0.5% versus 4.8%6 0.2% of body weight, respectively, n5 5;P5
2.8 × 1025). As previously described, the liver weight of male
Bcrp1;Mrp2;Mrp32/2 mice was ∼70% higher than that of wild-
type mice (Vlaming et al., 2009b). Despite the increased liver
size, detailed microscopic analysis of liver sections did not re-
veal obvious pathologic changes in either strain. An increase
(somewhat smaller) in liver weight was previously seen in other
Mrp2-deficientmouse strains (Vlaming et al., 2006, 2008, 2009a;
Tian et al., 2008).
Plasma Clinical Chemistry and Hematologic Analysis
of Bcrp1;Mdr1a/b;Mrp22/2 Mice. Plasma clinical chemistry
parameters in Bcrp1;Mdr1a/b;Mrp22/2 mice did not show
consistent significant differences from wild-type, except for
increased plasma bilirubin levels (conjugated and unconju-
gated), as previously shown for Bcrp1;Mrp22/2 mice (Vlaming
et al., 2009a). Additional deletion of Mdr1a/b did not further
affect the plasma bilirubin levels of the mice (data not
shown). Hematologic analysis of Bcrp1;Mdr1a/b;Mrp22/2
mice showed that hemoglobin levels were mildly but signifi-
cantly reduced compared with wild-type mice (males: 6.7 6
0.4 mM versus 7.4 6 0.1 mM; females: 6.8 6 0.1 mM versus
7.66 0.1mM, n5 3–5;P, 0.05). This was previously also found
in other Mrp2-deficient mouse strains (Vlaming et al., 2006,
2009a). Other measured parameters did not show consistent
differences with wild-type mice (not shown). Overall, despite the
complete absence of the three main apical detoxifying ABC
transporters, the Bcrp1;Mdr1a/b;Mrp22/2 mice displayed only
a few modest phenotypic alterations that were previously seen
in the single knockout strains. They appear, therefore, fully
amenable to pharmacological and toxicological studies.
Expression Levels of Metabolizing Enzymes and ABC
Transporters in Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;
Mrp2;Mrp32/2 Mice. We determined the RNA expression
levels of a set of genes involved in xenobiotic metabolism and
transport in general (Cyp3a11, Cyp3a13, Cyp3a25, Cyp3a41,
and Mrp4), as well as a number of genes that have been
associated with transport or metabolism of PhIP and/or its
main metabolites (Cyp1a1, Cyp1a2, Ugt1a1, Sult1a1, Nat1,
Nat2, Mdr1a, Mdr1b, and Mrp3) in liver, small intestine, and
kidney of male mice.
In liver, expression was significantly increased for
Cyp3a11, Cyp3a13, Ugt1a1, Mrp3, and Mrp4. Cyp3a11 and
Cyp3a25 were mildly (2.5- and 1.5-fold, respectively) in-
creased in livers of Bcrp1;Mdr1a/b;Mrp22/2 mice (Supple-
mental Table 1). Cyp3a13 was increased 3.1-fold in Bcrp1;
Mrp2;Mrp32/2 mice (P 5 0.043), but in all strains, Cyp3a13
RNA levels in liver were extremely low. Mrp4 protein was
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previously undetectable by Western blot in livers of wild-type
FVB and Bcrp1;Mrp2;Mrp32/2 mice (Vlaming et al., 2009b).
Accordingly, we found only extremely low levels ofMrp4 RNA
in livers of all strains, even though they were increased by 28-
and 43-fold in Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;
Mrp32/2 mice compared with wild-type mice, respectively
(P , 0.001 for both strains). Of the enzymes potentially
involved in PhIP metabolism, Ugt1a1 mRNA was mildly
increased (1.5- and 1.6-fold, respectively; P , 0.05 for both
strains) in livers of Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;
Mrp2;Mrp32/2 mice. Furthermore, Mrp3 mRNA levels in
Bcrp1;Mdr1a/b;Mrp22/2 mice were increased 4.5-fold com-
pared with wild-type (P 5 0.012). Moderately increased Mrp3
protein levels in liver were previously also found for other
Mrp2-deficient strains (Vlaming et al., 2006, 2009a).
In small intestine, only Cyp1a1 RNA was significantly
reduced in Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;Mrp32/2
mice, to 15 or 21% of wild-type values, respectively. None of
the other tested genes displayed significant or meaningful
alterations in expression in small intestine (Supplemental
Table 1).
In kidney, Cyp1a2 RNA was upregulated in Bcrp1;Mdr1a/
b;Mrp22/2, but not Bcrp1;Mrp2;Mrp32/2 mice, from an
undetectable expression level in wild-type mice (.40 poly-
merase chain reaction cycles). Cyp3a11 was also virtually
undetectable in wild-type and Bcrp1;Mrp2;Mrp32/2 kidneys
and increased 64-fold in Bcrp1;Mdr1a/b;Mrp22/2 kidneys,
but it was still very low compared with expression levels in
liver tissue (Supplemental Table 1). None of the other tested
genes was significantly changed, with the exception of a
12-fold increase in Mrp4 RNA (P , 0.05) in Bcrp1;Mdr1a/b;
Mrp22/2 kidneys, in line with what was found before for
Mrp4 protein levels in kidney of other Mrp2-deficient strains
(Vlaming et al., 2006, 2008, 2009a). Overall, changes in gene
expression in these strains were remarkably limited given
their genetic deficiencies in major detoxifying transporters.
Effect of ABC Transporters on Plasma and Tissue
Distribution of PhIP and Its Metabolites. As PhIP is
heavily metabolized in the body (Supplemental Fig. 1), and, as
only some of the known PhIP metabolites are potentially
carcinogenic (Schut and Snyderwine, 1999; Frandsen and
Alexander, 2000; Gooderham et al., 2001, 2002; Lauber et al.,
2004; Nakagama et al., 2005; Chen et al., 2007; Lauber and
Gooderham, 2007, 2011), we developed an LC-MS/MS assay
for the quantification of PhIP and N2-OH-PhIP in mouse
matrices (Teunissen et al., 2010) and expanded this assay for
detection of various phase 1 and phase 2 metabolites of PhIP
(Teunissen et al., 2011) We used this method to determine the
plasma and tissue concentrations of PhIP and its carcinogenic
metabolites 30 minutes after oral or intravenous administra-
tion of PhIP (1 mg/kg) to wild-type, Bcrp1;Mdr1a/b;Mrp22/2
and Bcrp1;Mrp2;Mrp32/2 mice. Overviews of all metabolites
detected in the tissues of the three strains are presented
in Supplemental Table 2 (intravenous administration) and
Supplemental Table 3 (oral administration). Most metabo-
lites, for example all glucuronide conjugates, are considered
detoxifying metabolites and do not have carcinogenic poten-
tial. Also, the formation of 49-OH-PhIP and subsequently
PhIP-49-sulfate (Supplemental Fig. 1) is considered a de-
toxification pathway. On the other hand, besides PhIP itself,
N2-OH-PhIP and the short-lived species PhIP-N-sulfate and
N-acetyl-PhIP are (pre)carcinogenic (Schut and Snyderwine,
1999; Frandsen and Alexander, 2000; Gooderham et al., 2001,
2002; Lauber et al., 2004; Nakagama et al., 2005; Chen et al.,
2007; Lauber and Gooderham, 2007, 2011). 5-OH-PhIP and
PhIP-5-sulfate are surrogate markers for the levels of the
ultimate genotoxic nitrenium radical cation that forms DNA
adducts (Supplemental Fig. 1) (Alexander et al., 2002).
PhIP and its main metabolite, N2-OH-PhIP, were detected
in the plasma of all mouse strains 30 minutes after
intravenous or oral administration of PhIP. No significant
differences between the strains were found (Fig. 1A; Supple-
mental Tables 2 and 3). After intravenous (but not oral)
administration, PhIP-5-sulfate was detected in plasma of both
knockout strains but not in wild-type plasma, suggesting that
Bcrp1 and/or Mrp2 influence the plasma levels of this marker
for genotoxic exposure (Supplemental Table 2). After oral, but
not after intravenous administration, the detoxification
product 49-OH-PhIP was quite abundant in plasma of all
strains, but no differences between strains were found
(Supplemental Table 3). The absence of 49-OH-PhIP in plasma
after intravenous administration suggests that this com-
pound is formed primarily by intestinal enzymes shortly after
oral administration. Indeed, Cyp1a1 and 1a2, which can form
this metabolite, are abundantly expressed in murine small
intestine (Ito et al., 2007). Although Cyp1a1 expression was
reduced in small intestine of both knockout strains (Supple-
mental Table 1), apparently this did not significantly affect
the formation of 49-OH-PhIP in these strains.
Thirty minutes after intravenous administration, in livers
of all strains, 1.8–2.5% of the given dose was found as
unchanged PhIP (Fig. 1B). Similar amounts of PhIP (2.7–
4.5%) were found in liver after oral administration (Fig. 1B).
No significant differences between the three strains were
found. Interestingly, in Bcrp1;Mrp2;Mrp32/2 mice, after both
intravenous and oral administration, the precarcinogen N2-
OH-PhIP accumulated significantly in the liver (Fig. 1, C and
D). This was not the case in the wild-type and Bcrp1;Mdr1a/b;
Mrp22/2 mice, suggesting that Mrp3 protein limits accumu-
lation of this metabolite in the liver. After intravenous
administration, the same was found for the mutagenesis
marker PhIP-5-sulfate (Fig. 1C). PhIP-5-sulfate was not
detected in the liver (and plasma; see above) after oral
administration.
The levels of the parent compound PhIP in the intestinal
tract (contents and tissue combined) were determined after
intravenous (Fig. 2A) or oral (Fig. 2B) application of PhIP
(1mg/kg). For both administration routes, the small intestinal
levels of PhIP in Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;
Mrp32/2 mice were reduced 4- to 6-fold compared with wild-
type mice. This finding suggests an important role for
Bcrp1 and/or Mrp2 in the hepatobiliary and/or intestinal
excretion of PhIP or, for oral administration, in reducing net
intestinal uptake. As there was no difference between the
Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;Mrp32/2 mice,
Mdr1a/b and Mrp3 are probably not involved here. Also, in
cecum and colon (the latter for intravenous application only)
of both combination knockout strains, PhIP concentrations
were reduced (Fig. 2, A and B). Small intestine levels of the
carcinogenic PhIP metabolite N2-OH-PhIP and the genotoxic
marker PhIP-5-sulfate were significantly reduced compared
with levels in wild-type in Bcrp1;Mdr1a/b;Mrp22/2 and
Bcrp1;Mrp2;Mrp32/2 mice, both after intravenous and oral
administration of PhIP (Fig. 2, C and D). This result suggests
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that Bcrp1 and/or Mrp2 are involved in biliary and/or direct
intestinal excretion of these metabolites. In addition, the
reduced levels of Cyp1a1 in small intestine tissue of the
knockout strains (Supplemental Table 1) may also lead to
reduced formation of N2-OH-PhIP in small intestine. How-
ever, after intravenous and oral administration, N2-OH-PhIP
levels in small intestine of Bcrp1;Mdr1a/b;Mrp22/2 mice
were even lower than levels in theBcrp1;Mrp2;Mrp32/2mice,
despite an insignificant difference in Cyp1a1 expression
between these strains. Besides PhIP, N2-OH-PhIP, and
PhIP-5-sulfate, various other PhIP metabolites (glucuronide
and sulfate conjugates) were detected in wild-type small
Fig. 1. Levels of PhIP and its primary carcinogenic metabolites in plasma and liver of male wild-type, Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;
Mrp32/2mice 30 minutes after intravenous (n = 4–11) or oral (n = 5) administration of PhIP (1 mg/kg). (A) PhIP and N2-OH-PhIP levels in plasma of the
strains after intravenous or oral administration. (B) PhIP levels in liver of the strains after intravenous or oral administration. (C) Levels of N2-OH-PhIP
and PhIP-5-sulfate in liver of the strains after intravenous administration. nd, not detected. Detection limits for N2-OH-PhIP and PhIP-5-sulfate were
0.02% and 0.01% of the dose, respectively (indicated by dashed lines). (D) N2-OH-PhIP levels in liver of the strains after oral administration. Data are
means 6 S.D. (n = 4–11; **P , 0.01; ***P , 0.001, compared with wild-type). In case tissue levels in wild-type mice were below the detection limit, the
LLQ 6 LLQ was used to calculate statistical significance.
Fig. 2. PhIP, N2-OH-PhIP, and PhIP-5-sulfate
levels in the intestinal tract (tissue and contents)
of male wild-type, Bcrp1;Mdr1a/b;Mrp22/2 and
Bcrp1;Mrp2;Mrp32/2 mice 30 minutes after in-
travenous (n = 4–11) or oral (n = 5) administra-
tion of PhIP (1 mg/kg). (A) Parent PhIP levels in
the intestinal tract of the strains after intrave-
nous administration. (B) Parent PhIP levels in
the intestinal tract of the strains after oral
administration. (C) N2-OH-PhIP levels in the
small intestine of the strains after intravenous or
oral administration. N2-OH-PhIP detection limit
was 0.02% of the dose, as indicated by the dashed
line. (D) PhIP-5-sulfate levels in the small
intestine of the strains after intravenous or oral
PhIP administration. PhIP-5-sulfate detection
limit was 0.02% of the dose (dashed line). Data
are means 6 S.D. (n = 4–11; *P , 0.05; **P ,
0.01; ***P , 0.001); nd, not detected; Sm. Int.,
small intestine. In cases where values were
below detection levels (nd), the statistical signif-
icance was calculated assuming values of LLQ 6
LLQ (mean 6 S.D.).
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intestine, after both intravenous and oral administration
(Supplemental Tables 2 and 3), but these were not detectable
in small intestines of the Bcrp1;Mdr1a/b;Mrp22/2 and
Bcrp1;Mrp2;Mrp32/2 mice, suggesting roles for Bcrp1 and/
or Mrp2 in the hepatobiliary and/or intestinal elimination of
these metabolites as well.
PhIP levels in kidney tissue 30minutes after intravenous or
oral administration were not significantly different between
the analyzed strains (Fig. 3A). However, in the kidneys of the
combination knockout mice, a significantly increased accu-
mulation was seen of various PhIP-metabolites, including the
(pre)carcinogen N2-OH-PhIP and genotoxicity marker PhIP-
5-sulfate (Fig. 3, B and C). For N2-OH-PhIP after intravenous
(but not oral) administration of PhIP, the increased kidney
levels were more pronounced in the Bcrp1;Mdr1a/b;Mrp22/2
mice than in the Bcrp1;Mrp2;Mrp32/2 mice. This may
perhaps be caused in part by the increased expression of
Cyp1a2 in the kidney of Bcrp1;Mdr1a/b;Mrp22/2 mice,
compared with wild-type and Bcrp1;Mrp2;Mrp32/2 mice
(Supplemental Table 1). Note that N2-OH-PhIP plasma levels
were not significantly different between these strains (Fig.
1A). Small amounts of PhIP-49-sulfate and PhIP-glucuronides
were also detected in the kidney after intravenous but not
after oral administration, and they were likewise increased in
both knockout strains (Fig. 3B). Thus, the combined absence
of Bcrp1 and Mrp2 leads to the accumulation of carcinogenic
PhIP metabolites in the kidney. These increases may be due
partly to reduced elimination of these compounds from the
kidney, but for PhIP-5-sulfate, they may also reflect higher
plasma exposure levels (Supplemental Table 2).
As previously shown in Bcrp12/2 mice (Enokizono et al.,
2008), the brain and testis penetration of PhIP after
intravenous administration was significantly increased
in Bcrp1-deficient mice (Fig. 3D; Supplemental Table 2). After
oral administration, similar effects of Bcrp1 absence were
observed, although not statistically significant in all cases, as
a result of high interindividual variation (Supplemental
Table 3). Interestingly, after intravenous administration,
the brain levels of PhIP were higher in the Bcrp1;Mdr1a/b;
Mrp22/2 mice compared with Bcrp1;Mrp2;Mrp32/2 mice
(0.13% 6 0.03% of the dose in Bcrp1;Mdr1a/b;Mrp22/2 mice
versus 0.06% 6 0.03% of the dose in Bcrp1;Mrp2;Mrp32/2
mice, n 5 4–7; P 5 0.007; Fig. 3D), even though PhIP plasma
levels were similar between the strains (Fig. 1A). This finding
suggests that besides Bcrp1, Mdr1a/b may also be involved in
restricting PhIP penetration into the brain. A similar effect
Fig. 3. PhIP and PhIP metabolite levels in kidney, brain, and testis of male wild-type, Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;Mrp32/2 mice 30
minutes after intravenous (n = 4–11) or oral (n = 5) administration of PhIP (1 mg/kg). (A) Parent PhIP levels in kidney of the strains after intravenous or
oral administration. (B) PhIP metabolite levels in kidney of the strains after intravenous administration. nd, not detected (below 0.003% of the dose,
indicated by the dashed line). (C) PhIP metabolite levels in kidney of the strains after oral administration. (D) PhIP levels in brain and testis of the
strains after intravenous administration. Data are means 6 S.D. (*P , 0.05; **P , 0.01; ***P , 0.001).
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was observed for the testis, although the difference between
Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;Mrp32/2 mice was
(just) not statistically significant (Fig. 3D).
Effect of Apical ABC Transporters on Biliary Excre-
tion of PhIP and Its Metabolites. Because the concen-
trations of PhIP and many of its metabolites in the intestinal
tract after intravenous and oral administration were signif-
icantly reduced in mice deficient in Bcrp1 and Mrp2, we
hypothesized that this could be caused by reduced biliary
excretion of these compounds. To investigate this, we
performed gallbladder cannulations in male wild-type and
Bcrp1;Mdr1a/b;Mrp22/2 mice and analyzed the biliary
excretion of PhIP and its metabolites in the first 60 minutes
after intravenous administration of PhIP (1 mg/kg). The
cumulative biliary excretion of PhIP was 41-fold lower in
combination knockout compared with wild-type mice (Fig.
4A), showing that Bcrp1, Mrp2, and (possibly, to a minor
extent) Mdr1a/b are the main transporters for biliary
excretion of PhIP. The biliary excretion of PhIP metabolites
(sulfate and glucuronide conjugates) was also dramatically
reduced in the Bcrp1;Mdr1a/b;Mrp22/2 mice (Fig. 4B).
Surprisingly, whereas the metabolite N2-OH-PhIP was
clearly detected in plasma andmany tissues after intravenous
and oral administration (Figs. 1–3), in bile of the mice this
compound could not be detected. This finding suggests that, in
contrast to PhIP, for this metabolite, which is formed both
intrahepatically and extrahepatically (Frandsen and Alexan-
der, 2000; Ma et al., 2007), biliary excretion is not a significant
route of elimination.
The plasma levels of PhIP and its metabolites at the end of
the gallbladder cannulation experiment are shown in Fig. 4C.
PhIP concentration was not significantly altered, but signif-
icant increases were seen in the concentrations of the
genotoxicity marker PhIP-5-sulfate (5.5-fold) and of OH-
PhIP-glucuronide (3.3-fold) in plasma of Bcrp1;Mdr1a/b;
Mrp22/2 mice, possibly as a consequence of the reduced
biliary excretion of these compounds. N2-OH-PhIP levels in
plasma were relatively low and not significantly different
between the strains (Fig. 4C). Interestingly, in the livers of
Bcrp1;Mdr1a/b;Mrp22/2 mice, despite highly decreased
biliary excretion (Fig. 4B) and mildly increased liver RNA
levels of Ugt1a1, OH-PhIP-glucuronide levels were signifi-
cantly reduced (0.06%6 0.02% of the dose in knockout versus
0.14% 6 0.05% of the dose in wild-type, P 5 5.2 × 1023). This
result suggests increased liver elimination of OH-PhIP-
glucuronides over the sinusoidal membrane in the Bcrp1;
Mdr1a/b;Mrp22/2 mice. PhIP levels in the liver of these
mice, like in plasma (Fig. 4C), tended to be somewhat higher
in the knockout strain, but this difference was not significant
(4.4% 6 2.1% of the dose in knockout versus 2.9% 6 1.0% of
the dose in wild-type, P5 0.18). Other PhIP metabolites were
not detected in livers of the mice after the gallbladder
cannulation experiment. To investigate the effect of Bcrp1,
Mrp2 and/or Mdr1a/b on the direct intestinal secretion of
PhIP and its metabolites, we also analyzed the small
intestinal contents of the mice after gall bladder cannulations
(Fig. 4D). The amount of PhIP in the small intestinal contents
was not significantly different between wild-type and Bcrp1;
Mdr1a/b;Mrp22/2 mice, suggesting that these transporters
do not affect direct intestinal excretion of unchanged PhIP.
However, the direct intestinal excretion of PhIP-5-sulfate
was, like the biliary excretion (Fig. 4B), dramatically lower in
the Bcrp1;Mdr1a/b;Mrp22/2 mice than in wild-type mice
(0.67 × 1023 6 1.5 × 1023% of the dose in knockout versus 14 ×
1023 6 5 × 1023% of the dose in wild-type, P5 6.3 × 1023), even
while the plasma concentration was markedly higher (Fig. 4,
C and D). For the other metabolites that were detected in the
intestinal contents (N2-OH-PhIP and OH-PhIP-glucuronides),
no differences between wild-type and knockout mice were
found.
Effect of ABC Transporters on Urinary and Fecal
Excretion of PhIP and Its Metabolites. As Bcrp1 and
Mrp2 apparently are the main transporters for the biliary
excretion of PhIP and some of its metabolites, we investigated
the urinary and fecal excretion of PhIP and its metabolites in
the first 24 hours after intravenous administration of PhIP
at 1 mg/kg to wild-type, Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;
Mrp2;Mrp32/2 mice. As shown in Fig. 5A, the urinary
excretion of PhIP was not altered in the combination knockout
mice, consistent with the absence of differences in plasma
concentration of PhIP observed 30 minutes after intravenous
(and oral) administration (Supplemental Tables 2 and 3). This
suggests that these three transporters are not involved in
urinary PhIP excretion (Fig. 5A). However, in line with the
reduced biliary excretion of PhIP in Bcrp1;Mdr1a/b;Mrp22/2
mice (Fig. 4A), the fecal excretion of PhIP was dramatically
reduced in Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;
Mrp32/2 mice, to 5% and 12% of wild-type excretion levels,
respectively (Fig. 5A).
Although urinary excretion of PhIP was not altered in the
combination knockout mice, the urinary excretion of some
important metabolites was altered (Fig. 5B). The urinary
excretion of the genotoxic exposure marker PhIP-5-sulfate
and the (pre)carcinogen N2-OH-PhIP, as well as the de-
toxification products PhIP-49-sulfate and OH-PhIP-glucuronide,
was substantially (3- to 10-fold) increased in both knockout
strains (Fig. 5B). This is in line with increased kidney
accumulation of these compounds (Fig. 3, B and C) and may
well reflect overall higher systemic exposure levels. No
significant differences were seen in urinary excretion of
PhIP and its metabolites between Bcrp1;Mdr1a/b;Mrp22/2
and Bcrp1;Mrp2;Mrp32/2 mice, suggesting a primary role
for Bcrp1 and Mrp2. Because of the abundant presence of
many interfering compounds, PhIP metabolite concentra-
tions in the feces of the mice could not be reliably quantified.
Discussion
We show here that Bcrp1;Mdr1a/b;Mrp22/2 mice, which
lack all the major apical multidrug efflux transporters, are
viable and fertile and show no obvious phenotypic aberrations
other than an increased liver weight and increased plasma
bilirubin levels, as previously found in Bcrp1;Mrp22/2 mice
(Vlaming et al., 2009a). In addition, only a few minor or modest
changes in RNA expression of some drug transporters and
metabolizing enzymes were observed. These mice should
therefore be valuable tools for studies on the relative and
combined effects of Bcrp1, Mdr1a/b and Mrp2 on the
pharmacokinetics, toxicity, and carcinogenicity of shared
substrates in vivo, especially in combination with the pre-
viously generated single and double knockout mice for these
transporters (Jonker et al., 2002; Vlaming et al., 2006, 2009a,b).
The exact mechanism behind the increase in liver weight
of the two mouse strains studied here, and of other knockout
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strains lacking Mrp2 (Vlaming et al., 2006, 2009a,b), is not
known. Likely, reduced detoxification of some compound(s)
that can affect liver size causes this effect, but the modest
changes we observed in expression of several other
functional detoxifying systems do not suggest a drastic
alteration in the overall functioning of the liver in these
mice.
In this first study with Bcrp1;Mdr1a/b;Mrp22/2mice,
combined with the Bcrp1;Mrp2;Mrp32/2 mice (Vlaming
et al., 2009b), we show that Bcrp1 and Mrp2 are the main
transporters responsible for the biliary, intestinal and fecal
excretion of the dietary carcinogen PhIP, as well as for the
biliary and/or direct intestinal excretion of the genotoxic
exposure marker PhIP-5-sulfate and several other PhIP
metabolites. The urinary excretion of PhIP was not altered
in the knockout mice, but the total PhIP excretion over 24
hours was markedly reduced. Furthermore, the combined
absence of Bcrp1 and Mrp2 leads to increased exposure of
plasma, liver, and kidney to potentially carcinogenic PhIP
metabolites like N2-OH-PhIP, as well as PhIP-5-sulfate, and
increased urinary excretion of all of these compounds. Asmost
PhIP-metabolizing enzymes, except for the mildly increased
Ugt1a1 in liver, were not differently expressed in both strains
compared with wild-type (Supplemental Table 1), the effects
observed are likely mostly caused by absence of Bcrp1 and/or
Mrp2. It appears that, when Bcrp1 and/or Mrp2 are absent,
PhIP is less readily removed from the body and probably
more extensively converted to metabolites, including carci-
nogenic ones. Since they also affect tissue distribution and
elimination of these metabolites (Figs. 2–5), Bcrp1 and Mrp2
may well be involved in protecting the body from PhIP-
induced carcinogenesis.
Fig. 4. Biliary excretion and plasma and small intestinal content levels of PhIP and its metabolites in the first 60 minutes after intravenous
administration of PhIP (1 mg/kg) to male gallbladder-cannulated wild-type and Bcrp1;Mdr1a/b;Mrp22/2 mice. (A) Cumulative biliary excretion of
parent PhIP. (B) Cumulative biliary excretion of PhIP metabolites. PhIP-5-sulfate was not detected (nd) in Bcrp1;Mdr1a/b;Mrp22/2 bile (LLQ was
1 × 1024% of the dose, indicated by the dashed line). N2-OH-PhIP and PhIP-49-sulfate were not detectable in wild-type or knockout bile. (C) Plasma
concentrations of PhIP and its metabolites at t = 60 minutes. (D) Small intestinal contents (Sm. Int. Cont.) levels of PhIP and PhIP metabolites at t = 60
minutes. Data are means 6 S.D. (n = 5; *P , 0.05; **P , 0.01; ***P , 0.001). In cases where values were below detection levels (nd), the statistical
significance was calculated assuming values of LLQ 6 LLQ (mean 6 S.D.).
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We additionally found that Mrp3 limits exposure of the
liver to N2-OH-PhIP and PhIP-5-sulfate, presumably by
mediating elimination of these compounds, after their
formation in the liver, across the sinusoidal membrane into
the blood. This process could thus have consequences for the
carcinogenic potential of N2-OH-PhIP elsewhere in the body.
However, we found substantially increased kidney levels and
urinary excretion of N2-OH-PhIP and PhIP-5-sulfate in both
knockout strains (Figs. 3, B and C, and 5B). Also the overall
urinary excretion of these compounds was not different
between Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;Mrp32/2
mice (Fig. 5B). We therefore conclude that although Mrp3
seems important for short-term sinusoidal liver elimination of
N2-OH-PhIP and PhIP-5-sulfate, this does not seem to
markedly affect their systemic exposure levels. Possibly other
basolateral ABC transporters, such asMrp4, can also gradually
transport these compounds from the liver (albeit more slowly
than Mrp3), or other tissues may contribute to N2-OH-PhIP
and PhIP-5-sulfate formation as well.
Similar to studies on rat Mrp2 by Dietrich et al. (2001a), we
found that mouse Bcrp1, Mrp2, and Mdr1a/b are not essential
for the urinary excretion of PhIP and its metabolites. Urinary
excretion of PhIP in each of the Bcrp1;Mrp2-deficient strains
was comparable to that in wild-type mice, and for many PhIP
metabolites, urinary excretion was even increased in the
knockouts, most likely as a consequence of increased plasma
concentrations of these compounds (Fig. 5). The latter may
result from reduced elimination by ABC transporters and
occasionally from mild increases in the formation of metab-
olites, for instance, from upregulation ofUgt1a1 in the liver of
both knockout strains and of Cyp1a2 in kidney tissue of
Bcrp1;Mdr1a/b;Mrp22/2 mice (Supplemental Table 1).
It is interesting to note that the brain accumulation of PhIP
was significantly, if modestly, increased in the Bcrp1;Mdr1a/
b;Mrp22/2 mice compared with Bcrp1;Mrp2;Mrp32/2 mice
(Fig. 3D). Since Mrp2 and Mrp3 are unlikely to play a role in
the blood-brain barrier of FVB mice, where they are not
detectably expressed (Soontornmalai et al., 2006; Agarwal
et al., 2012), this indicates that the combined deficiency of
Bcrp1 and Mdr1a/1b results in higher brain accumulation of
PhIP than the single deficiency of Bcrp1. Thus, not only Bcrp1
(Enokizono et al., 2008), but also Mdr1a/1b contributes to
protection of the brain from PhIP, consistent with the
observed modest in vitro transport of PhIP by Mdr1a (van
Herwaarden et al., 2003). The same may apply for the testis
penetration of PhIP in the combination knockout strains
(Fig. 3D).
This study shows that Bcrp1, Mrp2, and to some extent
Mdr1a/1b have a major impact on the exposure of the body to
PhIP, both its primary carcinogenic metabolites and a geno-
toxicity exposure marker. On the one hand, Bcrp1 and Mrp2
deficiency resulted in markedly reduced biliary and direct
intestinal excretion of PhIP and PhIP-5-sulfate and markedly
reduced short-term intestinal exposure to PhIP, N2-OH-PhIP,
and PhIP-5-sulfate as well as strongly decreased fecal
excretion of PhIP. On the other hand, the same deficiency
resulted in higher kidney and urinary levels of N2-OH-PhIP,
and markedly higher plasma, kidney, and urinary levels of
PhIP-5-sulfate. These data further indicate that the overall
systemic exposure to carcinogenic PhIP metabolites is in-
creased, whereas the intestinal exposure is decreased by
Bcrp1/Mrp2 deficiency. It is therefore possible that Bcrp1/
Mrp2 deficiency would have a pronounced effect on the
number and tissue distribution of PhIP-induced tumors, but
the direction of such effects in various tissues (increased or
decreased tumor formation) may not be so easy to predict.
Ultimately, only in vivo carcinogenesis studies can address
these questions.
It is interesting to note that Mrp2 (apical) and Mrp3
(basolateral) are generally expressed on opposite poles of
polarized cells in tissues analyzed in this study, such as
hepatocytes, enterocytes, and kidney tubular epithelial cells.
This might result in strongly increased tissue accumulation of
shared substrates of both of these transporters, when both are
deficient (i.e., in Bcrp1;Mrp2;Mrp32/2 mice). Survey of our
data, however, shows only a fewmetabolites that are consistently
Fig. 5. Urinary and fecal excretion of PhIP and its metabolites in the first 24 hours after intravenous administration of PhIP (1mg/kg) to male wild-type,
Bcrp1;Mdr1a/b;Mrp22/2 and Bcrp1;Mrp2;Mrp32/2 mice. (A) Urinary and fecal excretion of parent PhIP in the different strains. (B) Urinary excretion
of PhIP metabolites in the different strains. Data are means 6 S.D. (n = 5; *P , 0.05; **P , 0.01; ***P , 0.001). PhIP metabolite concentrations in the
feces could not be reliably quantified because of the presence of interfering compounds.
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and significantly accumulating more strongly in Bcrp1;Mrp2;
Mrp32/2 than inBcrp1;Mdr1a/b;Mrp22/2 tissues. These include
N2-OH-PhIP and PhIP-5-sulfate in liver, N2-OH-PhIP in small
intestine and PhIP-4’-sulfate in kidney. Given the substantial
other alterations in general PhIP and PhIP metabolite
disposition in these mice, we think such shifts may be difficult
to interpret in a straightforward manner.
Many polymorphisms and mutations in BCRP, MRP2,
MRP3, and P-gp are known, and these often lead to reduced
function (Huang, 2007; Maeda and Sugiyama, 2008). There
are even substantial numbers of individuals with partial or
complete genetic deficiencies in BCRP [e.g., Jr(a-) individuals]
(Saison et al., 2012) or in MRP2 (Dubin-Johnson syndrome).
Since PhIP is an abundant carcinogen, it will be of interest
to assess the effect of such ABC transporter deficiencies on
the carcinogenic potential of PhIP in epidemiologic studies.
Moreover, one can reasonably predict that the disposition of
many other dietary and environmental carcinogens, and their
hydroxylated, and sulfate- and glucuronide-conjugated acti-
vated derivatives will be markedly affected by these ABC
transporters as well. Our newly generated Bcrp1;Mdr1a/b;
Mrp22/2 andBcrp1;Mrp2;Mrp32/2mice should therefore not
only be valuable tools for pharmacokinetic studies of drugs,
but also for studies on the effect of the different ABC transporters
on limiting (or possibly increasing) xenobiotic-induced carcino-
genesis in vivo.
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